

Dr Eric Abadie
European Medicines Agency
7 Westferry Circus, Canary Wharf
London, E14 4HB
United Kingdom

Monheim am Rhein, 25 September 2008

Withdrawal of Lacosamide Pain MAA (EMEA/H/C/000894)

Dear Dr. Abadie,

I would like to inform you that, at this point of time, UCB Pharma S.A. has taken the decision to withdraw the application for Marketing Authorisation of Lacosamide Pain (film-coated tablets), which was intended to be used for the 'Treatment of diabetic neuropathic pain in adults'.

This withdrawal is based on the CHMP view that a relevant effect of lacosamide in diabetic neuropathic pain has not been convincingly established.

UCB Pharma is committed to continue the clinical development of lacosamide in the indication diabetic neuropathic pain. We reserve the right to make further submissions at a future date in this or other therapeutic indication(s). There are no consequences for patients currently included in clinical trials or compassionate use programmes with Lacosamide Pain.

The decision by UCB Pharma to withdraw the MAA for Lacosamide Pain does not affect Vimpat (lacosamide), authorised as adjunctive therapy in patients with partial-onset seizures.

I agree for this letter to be published on the EMEA website.

Yours sincerely